Education
About Us
Working with TipRanks
Follow Us
Covalon Technologies (TSE:COV)
:COV
RESEARCH TOOLSreports
Earnings Data
Report Date
Sep 01, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
0.04Last Year’s EPS
0.06Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 28, 2025
|% Change Since: -15.36%
|Next Earnings Date:Sep 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical research and financial stability, with promising growth in key markets and strategic partnerships. However, there were challenges in maintaining revenue and gross margins in Q2.Company Guidance
During Covalon's Q2 Fiscal 2025 earnings call, the company provided optimistic guidance, highlighting several key metrics and developments. Covalon reported strong revenue growth, particularly in their Vascular Access and Surgical Consumables and International sales channels, both of which saw growth of over 40% year-to-date. The company has maintained profitability with a positive adjusted EBITDA for the fifth consecutive quarter, and a robust cash position of over $18 million with zero debt. Covalon's US business has demonstrated a compound annual growth rate (CAGR) of over 30% over the past three years, significantly outpacing the mid-single-digit growth of the markets they operate in. The company is anticipating further growth in the second half of the fiscal year, driven by various initiatives including a clinical study on their VALGuard product, a new agreement with Paul Hartman USA, and strategic work with Origin Merchant Partners to explore joint ventures and M&A opportunities. Despite a slight dip in gross margins this quarter due to revenue mix, Covalon expects margins to improve as US sales pick up in the latter part of the year.VALGuard Clinical Study Success
A clinical study of Covalon's VALGuard Vascular Access Line Guard showed a significant reduction in bloodstream infections, leading to presentations at major scientific conferences and potential publication in a scientific journal.
Strong Financial Position
Covalon reported more than $18 million in cash on hand with zero debt, providing flexibility for future investments and shareholder value initiatives.
Growth in Key Markets
The US product revenue has grown at a three-year CAGR of more than 30%, outperforming the mid single-digit growth of the market. The Vascular Access and Surgical Consumables and International sales channels both had strong growth, each up more than 40% year-to-date over last year.
No Tariff Impact
Covalon has not incurred any tariff-related costs due to its North American-centric manufacturing strategy, which is a competitive advantage over competitors facing tariffs up to 30%.
Partnership with Paul Hartman USA
A new three-year agreement with Paul Hartman USA is expected to drive significant revenue growth for Covalon.
TSE:COV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:COV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 28, 2025 | C$2.80 | C$2.57 | -8.21% |
Feb 21, 2025 | C$3.18 | C$2.80 | -11.95% |
Jan 07, 2025 | C$3.59 | C$3.29 | -8.36% |
Aug 21, 2024 | C$2.76 | C$3.00 | +8.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Covalon Technologies (TSE:COV) report earnings?
Covalon Technologies (TSE:COV) is schdueled to report earning on Sep 01, 2025, TBA Not Confirmed.
What is Covalon Technologies (TSE:COV) earnings time?
Covalon Technologies (TSE:COV) earnings time is at Sep 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:COV EPS forecast?
TSE:COV EPS forecast for the fiscal quarter 2025 (Q3) is 0.04.